Founded in 2019, Genesis Molecular AI develops foundation models for molecular AI with the aim of enabling drug design and development, with a particular focus on protein targets that have resisted conventional approaches. The company was established to address the slow and expensive nature of traditional drug discovery, and it works at the intersection of deep learning, biotechnology and pharmaceuticals. More than $300M has been raised to fund this work.
Two products anchor the company's technology. GEMS (Genesis Exploration of Molecular Space) is its proprietary platform for molecular AI-driven drug discovery and the exploration of molecular space. Pearl is its foundation model, designed to help scientists discover medicines with high potency and selectivity. The company's technical domains span molecular AI, foundation models, deep learning, protein target modelling and molecular space exploration.
Genesis Molecular AI collaborates with industry leaders including Gilead and Incyte. Its team is composed of deep learning researchers, software engineers and drug discovery practitioners, working on the company's stated mission of bridging AI and biotechnology to transform drug discovery.
